ONT vs. PRTC, GNS, OXB, BVXP, CRW, SPI, UPR, AMS, BMK, and MXCT
Should you be buying Oxford Nanopore Technologies stock or one of its competitors? The main competitors of Oxford Nanopore Technologies include PureTech Health (PRTC), Genus (GNS), Oxford Biomedica (OXB), Bioventix (BVXP), Craneware (CRW), Spire Healthcare Group (SPI), Uniphar (UPR), Advanced Medical Solutions Group (AMS), Benchmark (BMK), and MaxCyte (MXCT). These companies are all part of the "medical" sector.
Oxford Nanopore Technologies (LON:ONT) and PureTech Health (LON:PRTC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, community ranking, risk, earnings, profitability, analyst recommendations and valuation.
PureTech Health has a net margin of 0.00% compared to Oxford Nanopore Technologies' net margin of -91.06%. PureTech Health's return on equity of -13.25% beat Oxford Nanopore Technologies' return on equity.
In the previous week, Oxford Nanopore Technologies' average media sentiment score of 1.30 beat PureTech Health's score of 0.00 indicating that Oxford Nanopore Technologies is being referred to more favorably in the media.
Oxford Nanopore Technologies has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500. Comparatively, PureTech Health has a beta of 0.93, suggesting that its share price is 7% less volatile than the S&P 500.
PureTech Health received 502 more outperform votes than Oxford Nanopore Technologies when rated by MarketBeat users. However, 100.00% of users gave Oxford Nanopore Technologies an outperform vote while only 86.58% of users gave PureTech Health an outperform vote.
Oxford Nanopore Technologies currently has a consensus target price of GBX 303.75, suggesting a potential upside of 168.87%. Given Oxford Nanopore Technologies' higher possible upside, research analysts clearly believe Oxford Nanopore Technologies is more favorable than PureTech Health.
38.5% of Oxford Nanopore Technologies shares are owned by institutional investors. Comparatively, 80.0% of PureTech Health shares are owned by institutional investors. 30.0% of Oxford Nanopore Technologies shares are owned by company insiders. Comparatively, 14.6% of PureTech Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
PureTech Health has lower revenue, but higher earnings than Oxford Nanopore Technologies. PureTech Health is trading at a lower price-to-earnings ratio than Oxford Nanopore Technologies, indicating that it is currently the more affordable of the two stocks.
Summary
PureTech Health beats Oxford Nanopore Technologies on 8 of the 15 factors compared between the two stocks.
Get Oxford Nanopore Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for ONT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ONT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Oxford Nanopore Technologies Competitors List
Related Companies and Tools
